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6ABBREVIATIONS
AFP alpha-fetoprotein
BO blighted ovum
EGF epidermal growth factor
FGF fibroblast growth factor
FGR fetal growth restriction
FSH follicle-stimulating hormone
hCG human chorionic gonadotrophin
HGF hepatocyte growth factor
IGF insulin-like growth factor
IL-1, -8 interleukin-1, -8
INF-α and -β interferon-α and -β
LIF leukaemia inhibitory factor
MA missed abortion
mab monoclonal antibody
mRNA messenger ribonucleic acid
PD-ECGF platelet derived endothelial cell growth factor
PlGF placenta growth factor
RT-PCR reverse transcription-polymerase chain reaction
rh recombinant human
RNA ribonucleic acid
Tek  (see Tie-2)
TGF-α, -β transforming growth factor-α and -β
Tie-1 tyrosine kinase with immunoglobulin and epidermal
growth factor-like extracellular domains
Tie-2 (Tek) tyrosine kinase with epidermal growth factor homology
TIMP tissue inhibitor of metalloproteinase
TNF-α tumour necrosis factor-α
VEGF-A, -B, -C vascular endothelial growth factor-A, -B, -C
VEGFR-1, -2, -3 vascular endothelial growth factor receptor-1, -2, -3
vWF von Willebrandt factor
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8INTRODUCTION
In normal pregnancy extensive vascular
development is essential for growth of the
placenta and fetus. Pregnancy-associated
angiogenesis is unique; it is the only
physiological condition where such rapid
and massive, yet tightly regulated vascular
growth occurs.
The physiological changes in the uterine
wall during pregnancy include the invasion
of trophoblasts into the uterine spiral
arteries, which are transformed into low
resistance vessels nourishing the placenta.
These changes fail to occur in pre-eclampsia
and sometimes also in association with fetal
growth restriction (Brosens 1977, Frusca
1989). In pre-eclampsia in particular, which
affects 2 to 7% of pregnancies (de Groot and
Taylor 1993), vascular dysfunction seems to
be a key feature of the disease (Roberts et al.
1989). During pregnancy in diabetic women,
pathological neovascular lesions, such as
retinopathy, tend to worsen (Klein 1990).
Diabetic women with nephropathy also
carry an increased risk of pre-eclampsia
(Landon and Gabbe 1994). Insufficient
angiogenesis may also have a role in
recurrent miscarriage, which affects
approximately 0.3-0.8% of childbearing
women (Houwert-de-Jong et al. 1989, Stirrat
1990).
The vascular endothelial growth factor
(VEGF) family of proteins, along with their
receptors, as well as the Tie receptors, play a
central role in embryonic vascular
development, and are expressed in the
placenta. They are associated with both
physiological and pathological
neovascularisation (Claesson-Welsh 1999).
This work was undertaken to study the role
of VEGF, its receptors, and Tie-receptors in
normal  and complicated pregnancies.
9REVIEW OF THE LITERATURE
Uncomplicated Pregnancy
Implantation
Implantation, i.e. the joining of the
conceptus and uterus, most often takes
place at the upper part of the uterus, and is
estimated to occur at about day 6 to 7 post-
conception. At around day 7 post-
conception the conceptus, which has now
become a blastocyst, is almost completely
embedded in the endometrium. It comprises
an inner cell mass surrounded by a layer of
trophoblast cells. The trophoblasts give rise
to the placenta and extraembryonic
membranes and the inner cell mass to the
embryo and umbilical cord. The outermost
trophoblasts invade the maternal
endometrium by penetrating between the
endometrial cells. These trophoblasts then
fuse to form the multinucleated syncytium.
Implantation is considered to be complete
by day 12 post-conception, by which time
fluid-filled lacunae have developed within
the syncytiotrophoblast (Kaufmann and
Burton 1994).
Changes in the uterine vasculature
At the onset of pregnancy major
physiological changes need to occur in the
vasculature of the uterine wall in order to
establish a functional interface between the
maternal and fetal circulations. Early in
pregnancy, extravillous cytotrophoblast
cells invade the decidualized uterine
endometrium and the inner third of the
myometrium. They migrate along the
maternal spiral arteries (endovascular
invasion), replace the endothelium and
musculoelastic tissue (Brosens et al. 1967),
and transform the arteries into large low
resistance vessels that are no longer
responsive to vasomotor influences
(Pijnenborg et al. 1983).
Although direct trophoblast invasion
undoubtedly plays a crucial role in the
uterine vascular changes, these changes
have been reported to occur before the
endovascular invasion of the trophoblasts
(Craven et al. 1998, Pijnenborg et al. 1983).
This observation has led to the suggestion
that the trophoblasts may release some
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vasoactive agents (Craven et al. 1998,
Pijnenborg et al. 1983), the precise nature
of which needs to determined.
Placental vasculature
In the human placenta, vasculogenesis, i.e. the de
novo synthesis of new blood vessels, accounts for
the majority of new vessel formation during the first
and second trimesters, and is initially observed
around day 19 post-conception (Demir et al. 1989).
Fetal capillaries appear complete around day 22
post-conception, and begin transporting fetal
erythrocytes by day 28. Capillary growth continues
in the last trimester, now resulting mainly from
angiogenesis, i.e. elongation and sprouting of pre-
existing capillaries (Benircshke and Kaufmann
1990). The primary sites of gas and nutrient transfer
are the peripheral non-muscularized intermediate
and terminal villi, which constitute the largest
proportion of placental volume (Kaufmann and
Burton 1994). A healthy placenta has a significant
reserve, as up to 50% infarction can occur without
fetal compromise (Gordon et al. 1995).
Complicated pregnancy
Recurrent miscarriage
Of all women known to be pregnant, some
10 to 15% miscarry (Knudsen et al. 1991).
The prevalence of recurrent miscarriages,
i.e. three or more consecutive miscarriages,
is estimated to be around 0.3-0.8% of all
diagnosed pregnancies (Houwert-de-Jong et
al. 1989, Stirrat 1990). Recurrent
miscarriage mostly remains an enigma
despite active research, but some
aetiological factors have been suggested.
These include chromosomal, endocrine and
immunological factors (Lim et al. ), as well
as uterine abnormalities (Houwert-de-Jong
et al. 1989, Tulppala et al. 1993). Attention
has also been paid to cytokines affecting
the endocrine and immune systems (Lim et
al. 1996).
Failure of physiological transformation of
uterine spiral arteries in spontaneous
miscarriage has been well documented
(Khong et al. 1987, Michel et al. 1990).
Whether these changes are constant in
women with recurrent miscarriages is not
known.
Pre-eclampsia
Pre-eclampsia affects 2-7% of all
pregnancies (de Groot and Taylor 1993).
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The aetiology of pre-eclampsia is still open,
but it is generally accepted that this multi-
organ failure is associated with vascular
endothelial dysfunction (Dekker and van
Geijn 1996, Morris et al. 1996, Mushambi
et al. 1996, Roberts et al. 1991, Roberts et
al. 1989). Circulating levels of several
endothelium-derived factors such as
prostacyclin (Ylikorkala et al. 1986),
fibronectin (Taylor et al. 1991), endothelin-
1 (Pouta et al. 1998), von Willebrandt
factor, tissue plasminogen activator and
plasminogen activator inhibitor (Friedman
et al. 1995) are, indeed, altered in pre-
eclampsia. In addition, increased
microvascular permeability and increased
coagulation are characteristic of this
complication (Perry and Martin 1992).
In pre-eclampsia, the invading
cytotrophoblasts only reach the superficial
decidua (Brosens et al. 1972), the
physiological changes in the placental bed
fail to occur (Frusca et al. 1989), and
placental perfusion is inadequate (de Groot
and Taylor 1993) (Figure 1). Looking more
closely at the invading trophoblasts, in pre-
eclampsia they fail to express some
adhesion molecules which are expressed in
healthy pregnancy (Zhou et al. 1997).
Fetal Growth Restriction
As in pre-eclampsia, in some cases of fetal
growth restriction (FGR) the uterine blood
Figure 1.
Schematic presentation of major changes
seen in uterine spiral arteries in
uncomplicated pregnancy, which are
absent in pre-eclamptic pregnancy.
vessels do not undergo adequate vascular
transformation (Brosens et al. 1977),
resulting in a diminished rate of blood
supply to the fetus. Detailed electron
microscopic studies on the placentas in
women with FGR and abnormal umbilical
artery waveforms in ultrasonography, have
demonstrated elongated villi covered with
wrinkled trophoblasts. The villous capillary
loops were also elongated, sparse in number,
12
exhibited relatively few branches, and were
mostly uncoiled (Krebs et al. 1996).
Undoubtedly, FGR involves vascular
disorganisation, the aetiology of which is
not yet known.
Diabetic pregnancy
Each year in Finland some 800 insulin-
treated women with type I diabetes give
birth. As in pre-eclampsia, in diabetic
pregnancies the fetuses are at an increased
risk of hypoxia, but in contrast to pre-
eclampsia, the fetuses and placentas tend to
grow larger than average. During
pregnancy the neovascular lesions of
diabetic retinopathy tend to worsen (Klein
et al. 1990). In addition, proteinuria often
increases during diabetic pregnancy, and
those diabetic women with nephropathia
have a particularly increased risk of pre-
eclampsia (Landon and Gabbe 1994). All
these complications may be related to
dysfunction of the vascular endothelium.
Vascular endothelial growth factor
(VEGF or VEGF-A)
Vasculogenesis, the de novo formation of
new blood vessels, and angiogenesis, the
formation of blood vessels by sprouting
from pre-existing ones, are processes
required in many physiological and
pathophysiological conditions, as well as
during embryonic development. During
embryogenesis the vascular system is the
first organ system to develop. Vascular
growth is controlled by a variety of
stimulating factors, such as the fibroblast
growth factors and insulin-like growth
factor, and a variety of inhibiting factors,
such as angiostatin and leukaemia
inhibitory factor (Folkman and Klagsbrun
1987, Gordon et al. 1995). Apart from
affecting vascular growth, these factors
have other effects as well. Vascular
endothelial growth factor (VEGF) is unique
in that it specifically targets the vascular
endothelium and is mitogenic for this
tissue.
Structure
The gene for VEGF, by alternative exon
splicing, produces five different VEGF
molecules, having 121, 145, 165, 189 and
206 amino acids (VEGF121, VEGF145,
VEGF165, VEGF189 and VEGF206,
respectively). VEGF165 is a 45 000 kDa,
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heparin-binding, homodimeric secreted
protein, although a significant fraction also
remains bound to the cell surface and
extracellular matrix (Ferrara and Henzel
1989). It is produced by a variety of normal
and transformed cells, and VEGF121 and
VEGF189 are also detected in the majority
of cells expressing the gene (Houck et al.
1991). VEGF206 is a rare form (Houck et
al. 1991), and VEGF145 has only recently
been identified (Poltorak et al. 1997).
VEGF165 is the most abundant form, and
from hereon the abbreviation VEGF refers
to VEGF165.
Function
Studies on knock-out mice have shown
VEGF to be crucial for embryonic
development. The null-mutation of one
VEGF allele results in a lethal phenotype
and the heterozygous embryos die at day
11-12 of development due to numerous
developmental anomalies of the vasculature
(Carmeliet et al. 1996, Ferrara et al. 1996).
Vascular endothelial growth factor also
seems to act as a survival factor for newly
formed capillaries (Alon et al. 1995) and is
capable of inducing vasodilatation and
hypotension in vivo (Ku et al. 1993, Yang
et al. 1996). It also induces microvascular
permeability and coagulation (Park et al.
1994, Senger et al. 1993). As a permeability
factor, VEGF is some 50 000 times more
effective than histamine (Dvorak et al.
1995). It is also considered to be
antiapoptotic (Meeson et al. 1999).
Sites of expression
Vascular endothelial growth factor is
expressed in the majority of adult and fetal
tissues as well as by various cultured cell
types (Houck et al. 1991). In human fetuses
of gestational age 16-22 weeks, abundant
VEGF mRNA expression has been
observed in the lung, kidney and spleen;
moderate expression in the heart, adrenal,
pancreas, intestine, liver, testis, skin,
muscle and brain; and only minimal
expression in the thymus (Shifren et al.
1994). VEGF has also been detected in the
circulation (Rodriguez et al. 1998) as well
as in saliva (Taichman et al. 1998).
In the non-pregnant uterus, VEGF
mRNA is seen in both the endo-
and myometrium (Charnock-Jones
et al. 1993, Harrison-Woolrych et
al. 1995, Torry et al. 1996), and in
the endometrium VEGF
immunoreactivity is seen
throughout the menstrual cycle (Li
et al. 1994). VEGF mRNA and
protein are also seen in the decidua
of the pregnant uterus (Ahmed et
al. 1995, Sharkey et al. 1993).
Several groups have provided data
on the expression of VEGF in the
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placenta in early and term
pregnancy. A review of this data is
given in the schematic presentation
in Figure 2.
Figure 2.
Review of earlier data on the expression of VEGF protein and mRNA in the placenta in the first
(A) and third (B) trimester of uncomplicated pregnancy.
Figure 2 A
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Figure 2 B
Regulation of expression
Expression of VEGF mRNA is rapidly and
reversibly induced by hypoxia both in vitro
and in vivo (Banai et al. 1994, Minchenko
et al. 1994). Its expression is also up-
regulated in both physiological and
pathological states where increased
angiogenesis occurs, e.g. in the uterine
endometrium and the ovaries during the
menstrual cycle (Cullinan-Bove and Koos
1993, Phillips et al. 1990), in healing
wounds (Brown et al. 1992), in synovial
fluid from patients with rheumatoid arthritis
(Fava et al. 1994, Koch et al. 1994) and in
the vitreous fluid of eyes troubled by
16
diabetic retinopathy (Aiello et al. 1994).
Increased VEGF production has also been
associated with endometriosis (Mclaren et
al. 1996), ovarian hyperstimulation
syndrome (Levin et al. 1998), and in
patients with hydatidiform mole (Nomura
et al. 1998). The various malignant tumours
expressing increased amounts of VEGF
include tumours of the female reproductive
tract, e.g. tumours of the ovary,
endometrium (Doldi et al. 1996) and the
uterine cervix (Guidi et al. 1995), as well as
tumours of the breast (Guidi et al. 1997).
It is well documented that steroid hormones
influence VEGF expression both in vivo
and in vitro. For example, in monkeys
progesterone induces endometrial stromal
cell VEGF expression, while the anti-
progestin mifepristone diminishes uterine
glandular VEGF immunoreactivity (Greb et
al. 1997). Human chorionic gonadotrophin
(hCG) stimulation in women enrolled in an
in vitro fertilization programme have
increased urinary VEGF concentrations
(Robertson et al. 1995). Injections of hCG
have also been associated with increased
serum VEGF levels in women at risk of
ovarian hyperstimulation syndrome
(Pellicer et al. 1999). The use of a
levonorgestrel-releasing intra-uterine
device seems to strengthen endometrial
VEGF immunoreactivity (Lau et al. 1999).
Data from work carried out in vitro on
steroid hormones and other factors is
summarized in Table 1.
Table 1. Factors shown to increase VEGF production in vitro
Compound Cell type Outcome Reference
cortisone human fetal adrenal cortical mRNA Shifren et al. 1998
dihydrotestosterone human epithelial prostatic mRNA Sordello et al. 1998
oestradiol bovine retinal pigment
epithelial
secreted protein Sone et al. 1996
oestradiol endometrial carcinoma mRNA Charnock-Jones et
al. 1993
oestradiol human endometrial mRNA Shifren et al. 1996
follicle-stimulating
hormone (FSH)
human granulosa-luteal mRNA Laitinen et al. 1997
glucose human smooth muscle mRNA, protein Natarajan et al. 1997
human albumin human luteinized granulosa mRNA Doldi et al. 1999
human chorionic
gonadotrophin (hCG)
human granulosa-luteal mRNA Laitinen et al. 1997,
Neulen et al. 1998
human relaxin human endometrial secreted protein Unemori et al. 1999
medroxyprogesterone-
acetate
human endometrial mRNA Shifren et al. 1996
progesterone bovine retinal pigment
epithelial
secreted protein Sone et al. 1996
VEGF-B
In 1996 two independent research groups
characterised a protein structurally related to
VEGF, and named it VEGF-related factor
(VRF) (Grimmond et al. 1996) or VEGF-B
(Olofsson et al. 1996a). By alternative
splicing, two mRNAs for VEGF-B are
generated, resulting in secretion of a 21 kDa,
167-amino acid-containing cell-bound form
and a 32 kDa, 186-amino acid-containing
form, which is freely secreted (Olofsson et
al. 1996a). VEGF-B binds to VEGFR-1
(Olofsson et al. 1998).
There is no clear evidence for the
mitogenicity of VEGF-B in vivo, and unlike
VEGF, hypoxia does not stimulate its
expression (Lagercrantz et al. 1996,
Olofsson et al. 1996a). Steroidal regulation
of VEGF-B has not been extensively
studied, but based on results from granulosa-
luteal cell cultures, VEGF-B mRNA levels
do not depend on those of FSH or hCG
(Laitinen et al. 1997). VEGF-B is able to
form mitogenically active heterodimers with
VEGF in vitro, but the presence of naturally
occurring VEGF-VEGF-B heterodimers has
not been documented (Olofsson et al.
1996b). The major sites of VEGF-B
expression are skeletal muscle and the heart
(Lagercrantz et al. 1996, Olofsson et al.
1996a). So far no clinical implications, such
as those associated with VEGF, have been
presented for VEGF-B.
VEGF-C
Parallel with the identification of VEGF-B,
another closely related protein designated
VEGF-related protein (Lee et al. 1996) or
VEGF-C (Joukov et al. 1996) was
characterised. The VEGF-C protein is
approximately 47 kDa, and like the other
members of this protein family, it is a
secreted homodimeric glycoprotein (Joukov
et al. 1996). VEGF-C binds to VEGF
receptors 2 and 3 (Joukov et al. 1996, Lee et
al. 1996).
VEGF-C is best known for its ability to
induce growth of the lymphatic vasculature
in vivo (Jeltsch et al. 1997). VEGF-C is also
mitogenic for vascular endothelial cells,
stimulates their migration, and acts as a
vascular permeability factor (Enholm et al.
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1998, Joukov et al. 1998). However,
concentrations of VEGF-C some 50-fold
higher than those of VEGF are needed to
induce vascular endothelial cell proliferation
(Park et al. 1994, Waltenberger et al. 1994).
In contrast to VEGF, hypoxia does not
increase VEGF-C mRNA levels (Enholm et
al. 1997).
VEGF-C is expressed in several adult and
embryonic tissues, but the major expression
sites of VEGF-C mRNA are the heart,
placenta, ovary, small intestine and thyroid
gland, as evidenced by Northern-blot
analyses (Joukov et al. 1996).
VEGF-D
VEGF-D was isolated as a fibroblast
growth factor, but was then noticed to have
strong structural similarities to the VEGF
family of growth factors (Orlandini et al.
1996, Yamada et al. 1997). It shares
features with VEGF-C: it binds to VEGF
receptors 2 and 3, is mitogenic towards
bovine aortic endothelial cells and has a
similar though not identical expression
pattern, i.e. strong expression in the heart,
muscle and small intestine (Achen et al.
1998, Joukov et al. 1996, Lee et al. 1996).
The role of VEGF-D in embryogenesis and
placental function remains to be explored.
Placenta growth factor (PlGF)
Structure
As its name implies, placenta growth factor
(PlGF), structurally related to the different
VEGF molecules introduced above, was
identified in a placental cDNA library
(Maglione et al. 1991). By alternative
splicing, two forms, PlGF-1 (PlGF131,
having 131 amino acids) and PlGF-2
(PlGF152, having 152 amino acids) are
generated. The longer form, PlGF152, is
heparin-binding, whereas the shorter form
is not (Maglione et al. 1993). The shorter
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form is capable of forming heterodimeric
molecules with VEGF in cells where both
genes are expressed (Cao et al. 1996a).
Function
In terms of vascular permeability, activity
and endothelial cell proliferation activity,
VEGF by far outdoes PlGF, as PlGF shows
only minimal activity (Park et al. 1994,
Sawano et al. 1996). PlGF does, however,
activate signalling pathways in both human
umbilical vein endothelial cells and
trophoblasts (Desai et al. 1999), and
promotes proliferation of extravillous
trophoblasts in vitro (Athanassiades and
Lala 1998). The mitogenic potency of the
PlGF/VEGF heterodimer falls between
those of PlGF and VEGF homodimers (Cao
et al. 1996a).
Sites of expression
The site of strongest PlGF expression is the
placenta, where PlGF protein and mRNA
are expressed throughout pregnancy
(Khaliq et al. 1999, Persico et al. 1999).
Khaliq et al. reported PlGF protein and
mRNA signals in the trophoblast bilayer as
well as in the villous mesenchyme (Khaliq
et al. 1999). Human umbilical vein
endothelial cells (Hauser and Weich 1993),
human amnion cells and choriocarcinoma
cell lines also express PlGF mRNA
(Persico et al. 1999).
In Northern blot analysis, PlGF mRNA has
also been detected in the brain, heart, lung,
skeletal muscle and thyroid (Persico et al.
1999), as well as in malignant solid
tumours (Khaliq et al. 1999, Persico et al.
1999).
Regulation of expression
There is controversial data on the effect of
hypoxia on PlGF expression. It was earlier
shown that, opposite to VEGF mRNA,
hypoxia had no effect on PlGF mRNA
expression in several cell lines (Cao et al.
1996b, Viglietto et al. 1996). Hypoxia did,
however, result in increased protein
excretion into culture media of chorion
carcinoma cells (Cao et al. 1996a).
Recently, Khaliq et al. demonstrated down-
regulation of both PlGF mRNA and protein
by hypoxia in trophoblasts (Khaliq et al.
1999).
Few clinical data on PlGF are available, but
an association with diabetic retinopathy is
based on the finding of PlGF in vitreous
humour samples from diabetic patients, in
contrast to no detectable PlGF in control
samples (Cao et al. 1996b, Khaliq et al.
1998, Viglietto et al. 1996).
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Receptors of the VEGF family
The VEGF family of growth factors binds to
at least three different tyrosine kinase
receptors. These receptors, VEGF receptor-1
(VEGFR-1), -2 and -3 dimerize in response
to growth factor-binding and become
tyrosine phosphorylated upon activation
(Shibuya et al. 1999, Ullrich and
Schlessinger 1990).
VEGF receptor-1 and –2
Structure
VEGFR-1 or Flt-1 (fms-like tyrosine kinase)
was first described in 1990 (de Vries et al.
1992, Shibuya et al. 1990). In addition to
VEGF, this 180 kDa receptor also binds
PlGF and VEGF-B, although with less
affinity (Park et al. 1994, Sawano et al.
1996).
VEGFR-2 (or KDR) shares close structural
similarity with VEGFR-1 (Terman et al.
1992). The name Flk-1 refers to the mouse
analogue (Matthews et al. 1991). The mature
receptor is a 230 kDa glycosylated protein
(Sait et al. 1995, Takahashi and Shibuya
1997) which binds VEGF (Millauer et al.
1993, Terman et al. 1992) and a short form
of VEGF-C (Joukov et al. 1997) (Figure 3).
Function and Localization
Studies on animals have shown both
VEFGR-1 and -2 to be highly specific for
vascular endothelium throughout the body
(Jakeman et al. 1992). In addition, these
receptors have been detected in the placenta
and in uterine smooth muscle cells (Brown
et al. 1997) (Table 2).
Hypoxia up-regulates VEGFR-1 expression,
but not that of VEGFR-2 (Gerber et al.
1997). Null-mutation of VEGFR-1 and
VEGFR-2 in mice results in embryonic
death at day 8.5-9.5 (Fong et al. 1995,
Shalaby et al. 1995). In VEGFR-1-deficient
mice the tubular cardiovascular system had
been almost completely established, but the
endothelial cell layers on the vascular walls
were not well organized (Fong et al. 1995).
Lack of VEGFR-2, however, resulted in lack
Figure 3.
Schematic presentation showing binding of VEGF, PlGF, and their heterodimer to their
receptors. sVEGFR-1 = soluble VEGFR-1.
of endothelial cells, and development of the
cardiovascular system was severely
impaired (Shalaby et al. 1995).
Soluble forms
A secreted, shorter form of VEGFR-1,
comprising the extracellular part of full-
length VEGFR-1, is known to occur in vivo
(Kendall and Thomas 1993, Kendall et al.
1996). A soluble form of VEGFR-2
(sVEGFR-2) has also been generated
(Röckl et al. 1998). sVEGFR-1 clearly
binds to VEGF and blocks its mitogenic
activity, while sVEGFR-2 does not (Clark
et al. 1998a, Kendall and Thomas 1993,
Röckl et al. 1998).
Table 2. Summary of data on VEGFR-1 and VEGFR-2 expression in human placenta
Tissue Method Result Reference
VEGFR-1
Placenta Northern blotting present Barleon et al. 1994
Isolated 3rd trimester
trophoblast
RT-PCR present Shore et al. 1997
1st and 3rd trimester
placenta
mRNA in situ
hybridization
expressed in villous
cytotrophoblast
Charnock-Jones et al. 1994
VEGFR-2
Placenta Northern blotting present Barleon et al. 1994
Isolated trophoblast RT-PCR not present Shore et al. 1997
1st and 3rd trimester
placenta
immunohisto-
chemistry
expressed in villous
vascular endothelium
Vuckovic et al. 1996
VEGF receptor-3 (VEGFR-3)
VEGFR-3, or Flt-4, is an approximately
195 kDa protein that binds VEGF-C and
VEGF-D (Fig. 4). A shorter truncated form
is also synthesized, but the longer form is
the major one to be detected in tissues
(Eriksson and Alitalo 1999, Borg et al.
1995). During embryogenesis, VEGFR-3 is
first expressed in both vascular and
lymphatic endothelium, but during later
development it becomes restricted to the
lymphatic system (Kaipainen et al. 1995).
Mice devoid of VEGFR-3 die in utero after
embryonic day 10, as large blood vessels
fail to develop (Dumont et al. 1998) (Figure
4).
Figure 4.
Schematic presentation showing binding of VEGF-B, VEGF-C and VEGF-D to their receptors
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Tie-1 and Tie-2 receptors
Structure
Another receptor family specific for the
vascular endothelium comprises Tie-1, a 117
kDa protein (or tie, tyrosine kinase with
immunoglobulin and epidermal growth
factor-like homology domains) and Tie-2 (or
tek, tunica interna endothelial cell kinase)
receptors (Sato et al. 1993).
Expression and Function
During embryogenesis the expression of
Tie-1 and Tie-2 follows that of VEGFR-1
and VEGFR-2, but antedates that of von
Willebrandt factor, a marker of more mature
vascular endothelium (Dumont et al. 1992,
Dumont et al. 1995, Yamaguchi et al. 1993).
Knock-out studies have revealed lack of
vascular integrity in Tie-1- and Tie-2-
deficient mice (Dumont et al. 1994, Puri et
al. 1995, Sato et al. 1995). Tie-1 null-
mutated embryos show, for example, a
diminished number of endothelial cells and
degeneration of the heart endocardium
(Dumont et al. 1994, Sato et al. 1995), and
Tie-2 null-mutated embryos show oedema
and haemorrhage (Puri et al. 1995, Sato et
al. 1995).
The expression of Tie-1 is enhanced in
physiological and pathological angiogenesis,
such as maturation of ovarian follicles, wound
healing and tumour angiogenesis (Hatva et al.
1994, Kaipainen et al. 1994, Korhonen et al.
1992). The ligand for Tie-2, angiopoietin-1, was
identified in 1996, but the ligand for Tie-1
remains to be identified (Davis et al. 1996). An
endogenous antagonist to Tie-2, angiopoietin-2,
has also been discovered (Maisonpierre et al.
1997). Interestingly, VEGF stimulates the
release of soluble Tie-1 from human endothelial
cells (Yabkowitz et al. 1999).
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VEGF and clinical medicine
VEGF and pre-eclampsia
On the basis of the above, it is easy to
hypothesize that expression of VEGF
family members and the Tie-receptors
would be affected by pre-eclampsia. Little
is known about the role of the Tie-
receptors, but some earlier work,
summarized in Table 3, was carried out to
study the relationships between VEGF
expression and pre-eclampsia.
Table 3. Changes in VEGF expression and levels in samples
from pre-eclamptic subjects compared with healthy controls
Sample Direction of change Reference
mRNA from placenta decrease Cooper et al. 1996
protein from placenta increase Khaliq et al. 1999
protein in placental
syncytiotrophoblast
decrease Lyall et al. 1997
maternal serum increase Baker et al. 1995
maternal serum decrease Lyall et al. 1997
maternal plasma increase Kupferminc et al. 1997
maternal plasma increase Sharkey et al. 1996
VEGF and diabetes mellitus
In non-pregnant women VEGF is
associated with diabetic retinal
neovascularization (Aiello et al. 1994). It is
not known whether VEGF plays a role in
the worsening of retinopathy during
pregnancy. Interestingly, however,
progesterone, when administered at
concentrations physiological in pregnancy,
increases the production of VEGF by
bovine retinal pigment epithelial cells
(Sone et al. 1996), and diabetic pregnant
women with retinopathy are known to have
higher second trimester serum progesterone
levels than those without retinopathy
(Larinkari et al. 1982).
Decreased VEGF production in the kidneys
of diabetic subjects has been demonstrated
(Shulman et al. 1996), but it is not known
whether in diabetic pregnant women VEGF
plays a role in the proteinuria which often
increases with advancing pregnancy.
In hind-limb ischaemia of diabetic mice the
ischaemic tissues show lower VEGF
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protein and mRNA levels than the
ischaemic tissues of non-diabetic mice.
Intramuscular injections of an adenoviral
vector containing VEGF successfully
resulted in neovascularization (Rivard et al.
1999). Diabetes might thus be associated
with reduced responsiveness of VEGF to
hypoxia, a notion which might provide help
in understanding the molecular biology of
placental hypoxia in diabetic women.
Other clinical perspectives
regarding VEGF
As a result of its angiogenesis-promoting
effects, VEGF is an appealing candidate for
therapy of any disease where decreased
circulation constitutes a problem. In 1996
Isner et al. published a case report on a
patient with an ischaemic limb. They
transferred VEGF DNA plasmids to the
popliteal artery, resulting in an increase in
collateral vessels in the lower part of the
leg, as well as increased blood flow (Isner
et al. 1996).
Much attention has also been paid to the
inhibition of VEGF activity at sites of
undesired vascular growth. Animal studies
have, indeed, shown promising results on
regression of tumour size when
chemotherapy was combined with
administration of antibodies against VEGF
(Borgström et al. 1996, Kim et al. 1992).
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AIMS OF THE STUDY
Rapid vascular growth, as well as its regulation, are essential features of successful pregnancy.
In complicated pregnancies such as those in women with recurrent miscarriage, pre-eclampsia,
diabetes or fetal growth restriction, disturbances in this regulation may occur. Based on the
results of animal studies, the VEGF family, along with VEGF receptors, as well as Tie
receptors, specifically affect the vasculature, and are crucial for the continuation of pregnancy.
Hence, the present work was designed to evaluate their roles in the above-mentioned pregnancy
complications.
The specific aims were:
- to localize VEGF, VEGFR-1, VEGFR-2,
VEGFR-3, Tie-1 and Tie-2 in placentae of
early uncomplicated pregnancies
- to evaluate whether the expression of
VEGF, VEGFR-1, VEGFR-2, VEGFR-3,
Tie-1 and Tie-2 in the early placenta and
decidua is altered in women suffering from
unexplained recurrent miscarriages
- to localize VEGF, PlGF and Tie-1 in
healthy term placenta, and to study whether
the placenta expresses VEGF-B and VEGF-
C
- to study circulating concentrations of Tie-
1 in umbilical venous and arterial as well as
maternal venous blood, and to compare
possible differences between healthy and
pre-eclamptic subjects
- to study possible factors binding VEGF in
the maternal circulation and amniotic fluid
in early and term uncomplicated pregnancy
- to compare amniotic fluid soluble
VEGFR-1 concentrations in uncomplicated
and complicated pregnancies
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MATERIALS AND METHODS
All study subjects were recruited following informed consent and in agreement with the local
ethics committee. Patient samples analysed are given in tables 4-5. In addition, culture media
from 20 placental biopsies performed at gestational weeks 10-12 were obtained from the
Department of Antenatal Diagnostics (IV). Biopsies had been performed for assessment of fetal
chromosomes from women over 40 years of age, and all samples had normal karyotypes.
Methods used are given tables 6-9.
Table 4. Description of samples of pregnant women (II-IV) and those undergoing legal
termination of early pregnancy (I). Patients were recruited from the antenatal wards and day
surgery wards of the Department of Obstetrics and Gynaecology, Helsinki University Central
Hospital.
Subjects
     Sample
Subjects n Gestational age (weeks)
at sample collection
Used in
Amniotic fluid Healthy women
Women with pre-eclampsia
Women with diabetes mellitus
Women with diabetes mellitus and
superimposed pre-eclampsia
Women with fetuses suffering from growth
restriction
35
50
29
11
22
34
11
14
14-19
15-17
25-39
38-39
28-39
27-39
32-37
37-36
V
IV
V
IV
V
V
V
V
Peripheral
venous blood
Healthy women
Women with pre-eclampsia
15
54
40
40
15
10-13
14-40
38-41 and
on 1st post partum day
38-40 and
on 3rd post partum day
29-33 and
on 1st post partum day
IV
III
III
IV
III
Placenta Healthy women 5 38-41 II
Placenta and
decidua
Healthy women
Women experiencing recurrent miscarriages and
present
     Missed abortion
     Blighted ovum
12
12
6
7-11
7-11
7-11
I
I
I
Umbilical blood
     Venous
     Arterial
Infants of healthy mothers
Infants of pre-eclamptic mothers
Infants of healthy mothers
24
24
8
14
13
38-40
38-40
39-33
38-41
38-40
III
IV
III
III
IV
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Table 5. Description of samples of non-pregnant women.
Samples Subjects n Phase of menstrual
cycle
Used in
Blood samples Healthy women
No medication
Oral contraceptives
22
22
11 of the above
12
Follicular phase
Follicular phase
Throughout cycle
Follicular phase
IV
III
III
III
Table 6. Laboratory methods used
Method Used in
Enzyme-linked immunosorbent assay (ELISA) IV, V
Gel filtration IV
Immunofluorometric assay III
Immunohistochemical protein staining I, II
Isoelectric focusing IV
mRNA in situ hybridization and Northern hybridization II
Radio-iodination of protein IV
Table 7. Description of plasmids used in mRNA in situ
hybridization and in Northern blotting
Plasmid Description Reference
VEGF nt 57-639 Keck et al. 1989
VEGF-B nt 1-382 Olfsson et al. 1996a
VEGF-C nt 1-555 Jeltsch et al. 1997
PlGF nt 304-944 Maglione et al. 1991
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Table 8. Primary antibodies used in immunohistochemistry
Antibody Description Source Used in
VEGF mouse antiserum
rabbit antiserum
R&D Systems1
Santa Cruz Biotechnology2
II
I
PlGF rabbit antiserum Dr. M. G. Persico3 II
VEGFR-1/Flt1 rabbit antiserum Santa Cruz Biotechnology I
VEGFR-2/KDR rabbit antiserum Santa Cruz Biotechnology I
VEGFR-3/Flt-4 rabbit antiserum Santa Cruz Biotechnology I
Tie-1 rabbit antiserum Dr. P. Batard4
Santa Cruz Biotechnology
II
I
Tie-2 rabbit antiserum Santa Cruz Biotechnology I
von Willebrand factor rabbit antiserum Dako5 I, II
Vimentin mouse antiserum Dako I
Cytokeratins 8, 14,
15, 16, 18 and 19
mouse antiserum (MAK ) Zymed
Laboratories Inc. 6
I
1Abingdon, UK, 2Santa Ana, CA, USA, 3International institute of Genetics and Biophysics,
Naples, Italy, 4Laboratoire de biologie molecularie et cellulaire des facteurs de croissance,
Villejuif, France, 5Glostrup, Denmark, 6San Fransisco, CA, USA.
Table 9. Statistical analyses used
Analysis Used in
Descriptive statistics III, IV
Comparison of data between groups
     Student's unpaired t-test IV
     Mann-Whitney U-test III, V
Comparison of data within a group
     Wilcoxon test III
Associations between different parameters
     Spearman's rank correlation III, V
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RESULTS
VEGF, VEGFR-1, -2, -3 and Tie-1 and -2 in recurrent
miscarriage (Study I)
In order to find out whether the expression
of VEGF, VEGFR-1, -2 or -3 or that of Tie-
1 or -2 receptors is altered in recurrent
miscarriage, placental and decidual tissue
was analyzed by immunohistochemistry.
Patients with recurrent miscarriage were
analyzed as two groups according to
whether the present pregnancy was
diagnosed as missed abortion (MA) or
blighted ovum (BO).
Equally strong staining for von Willebrandt
factor, vimentin and the cytokeratin
cocktail MAK were seen in all study
groups, indicating no general protein
degradation. This allowed comparison of
the staining intensities of the antigens under
study, which showed tissue- and cell-
specific differences between the groups.
The main observations included, compared
with the controls, 1) diminished placental
trophoblastic VEGF immunoreactivity in
the BO and MA groups, 2) weaker
VEGFR-1 and -2 immunoreactivity in
decidual vascular endothelium in the BO
and MA groups, 3) absence of VEGFR-3
immunoreactivity in decidual vascular
endothelium of all study groups, 4) reduced
placental trophoblastic Tie-1
immunoreactivity in the BO and MA
groups, and 5) reduced decidual vascular
endothelial Tie-1 and Tie-2
immunoreactivity in the MA and BO
groups.
In one sample from the healthy controls
massive invasion of trophoblasts into the
decidua was seen. These trophoblasts were
negative for VEGF, VEGFR-1, VEGFR-2
and VEGFR-3, but strongly positive for
Tie-1 and Tie-2.
In the group of patients with recurrent
miscarriages and present blighted ovum,
blood vessel-like structures negative for
von Willebrandt factor were seen. These
luminal structures were, however, positive
for VEGF, VEGFR-1, -2, -3 and for Tie-1
and -2.
Localization of VEGF, PlGF and Tie-1 in healthy
term placenta (Study II)
Localization of VEGF, PlGF and Tie-1 in
healthy term placentae was investigated
immunohistochemically, and that of VEGF
and PlGF mRNAs by in situ hybridization.
The presence of VEGF-B and VEGF-C
mRNAs in the placenta was evidenced by
Northern blotting.
VEGF-B and VEGF-C mRNA expression
appeared to be stronger than that of VEGF
mRNA, as they produced stronger bands in
Northern blots. VEGF mRNA was
localized to the chorionic mesenchyme, and
the protein mainly to villous vascular
endothelium. A little immunoreactivity was
also observed in the villous stroma. Unlike
VEGF, PlGF mRNA was not observed in
the chorion, but in the villous trophoblasts.
PlGF protein staining was similar to that of
VEGF, i.e. strong staining in the villous
vascular endothelium and some staining in
the villous stroma.
Tie-1 immunoreactivity was distinct in the
villous vascular endothelium, but also
present in the villous trophoblasts. Neither
Tie-1 nor VEGF or PlGF proteins were
seen in the maternal decidua or the chorion.
Maternal serum Tie-1 in healthy and pre-eclamptic
pregnancy (Study III)
A time-resolved immunofluorometric assay
was developed for detection of the soluble
extracellular domain of Tie-1 by authors
Marja-Terttu Matikainen, PhD, and
professor Kari Alitalo, MD. The assay was
used to demonstrate the presence of Tie-1
in sera from non-pregnant women, pregnant
women at term and postpartum, and from
the umbilical circulation.
 In sera from healthy pregnant women, Tie-
1 levels decreased with advancing
gestational age after 26 weeks (r=0.6,
p>0.001). At term, they were higher
(median 233 ng/ml, range 152-414 ng/ml)
than those of non-pregnant women (median
173 ng/ml, range 107-333 ng/ml, p<0.001).
These levels were also higher than those of
women with pre-eclampsia at term (median
32
152 ng/ml, range 90-372 ng/ml, p<0.05).
This difference between healthy (median
221 ng/ml, range 128-343 ng/ml) and pre-
eclamptic (median 144 ng/ml, range 93-310
ng/ml) pregnant women also persisted on
the first postpartum day (p<0.05).
The median Tie-1 levels in umbilical
venous blood from healthy infants were
higher (340 ng/ml, range 245-690 ng/ml)
than in corresponding arterial blood (240
ng/ml, range 174-474 ng/ml, p<0.001), with
a positive correlation between the venous
and arterial levels (r=0.07, p<0.05).
Umbilical venous Tie-1 levels in infants of
pre-eclamptic women (median 389 ng/ml,
range 291-391 ng/ml) did not differ from
those of healthy infants. Both the umbilical
arterial and venous Tie-1 levels in healthy
infants, as well as the venous levels in
infants of pre-eclamptic mothers, were
lower than the corresponding maternal
levels (p<0.001, p<0.05 and p<0.05,
respectively).
In non-pregnant women, no difference in
serum Tie-1 levels was observed between
women using oral contraceptives (median
166 ng/ml, range 134-333 ng/ml) and those
who did not (median 206 ng/ml, range 107-
306 ng/ml). Serum Tie-1 levels did not vary
with the menstrual cycle.
VEGF-binding activity in amniotic fluid and maternal
serum (Study IV)
In this work VEGF-binding activity present
in amniotic fluid and maternal serum was
investigated.
We first observed that added VEGF was
not recovered in early or term amniotic
fluid or maternal serum. However, added
VEGF was fully recovered in maternal
postpartum serum, in serum from the
umbilical vein or artery, and in sera from
non-pregnant subjects. Added PlGF,
however, was fully recovered in all samples
studied. On the basis of serial dilution of
the samples, the strongest VEGF-binding
activity was observed in amniotic fluid,
especially at term.
The VEGF-binding activity was related to a
compound with a molecular weight of
approximately 440 kDA and an isoelectric
point of approximately 8. These figures
differed from those of the high molecular
weight compounds alpha-2-macroglobulin,
pregnancy zone protein and pregnancy-
associated plama protein-A, and the
possibility of their binding to VEGF was
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also ruled out by immunodiffusion
experiments.
Characterization of the nature of binding of
VEGF to the high molecular weight
complex revealed that radio-iodinated
VEGF was not dissociated from the
complex by either high concentrations of
NaCl or by heparin, but it was dissociated
by 4 M KSCN and low pH.
Soluble VEGFR-1 in amniotic fluid in normal and
complicated pregnancy (Study V)
This descriptive study was designed to
analyze the amniotic fluid concentrations of
sVEGFR-1 in normal pregnancies and
those complicated by pre-eclampsia,
diabetes, diabetes with superimposed pre-
eclampsia, or fetal growth restriction.
Amniotic fluid concentrations of sVEGFR-
1 appeared to be gestational age-dependent,
as in normal early pregnancy the levels
were higher (median 22 ng/ml, range 2.3 -
29.5 ng/ml) than at term (median 13 ng/ml,
range 0.5 - 32 ng/ml, p<0.05). During the
third trimester, pre-eclamptic women had
higher levels (median 20 ng/ml, range 10.5
- 37 ng/ml) than the healthy controls
(p<0.05). The lowest third trimester levels
were found in diabetic women (median 11
ng/ml, range 0.5 - 27 ng/ml). When pre-
eclampsia was superimposed on diabetes,
amniotic fluid concentrations of sVEGFR-1
were lower (median 13 ng/ml, range 6 - 32
ng/ml) than in women with pre-eclampsia
alone. Amniotic fluid concentrations of
sVEGFR-1 in women whose fetuses
suffered from growth restriction (median
19.5 ng/ml, range 5 to 40 ng/ml) did not
statistically differ from those of healthy
controls. The amniotic fluid levels of
sVEGFR-1 did not correlate to those of
erythropoietin.
The placenta was shown to secrete
sVEGFR-1, as it was detected in culture
media from 20 first trimester placental
biopsies (median 14 ng/ml, range 9 - 20
ng/ml).
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DISCUSSION
VEGF, VEGFR-1, -2, -3 and Tie-1 and -2 in the first
trimester placenta – Changes in recurrent
miscarriage
In study I, VEGF, the three VEGF
receptors as well as the Tie receptors were
localized in first trimester placenta. As the
aetiology of early pregnancy recurrent
miscarriage most often remains open,
tissues from women suffering from them
were also analyzed. Inadequate
physiological adaptation of the uterine
blood vessels in miscarriage has been
reported (Khong et al. 1987, Michel et al.
1990), and thus it is easy to hypothesize
that the VEGF or Tie families could play a
role in these events.
We confirmed an earlier finding by Clark et
al. (1996), who demonstrated VEGF
immunoreactivity in placental trophoblasts
as well as in the decidua of early pregnancy
in healthy subjects. However, in our
patients with recurrent miscarriages, the
placental trophoblasts were mostly negative
for VEGF, which gives support to the
hypothesis of a role of VEGF in recurrent
miscarriage. However, it is not possible to
say whether these changes are primary or
secondary to this condition.
We observed that in decidual but not
placental vascular endothelium, the staining
intensities of VEGF, VEGFR-1 and
VEGFR-2 in the MA group were
diminished compared with the controls.
One might thus speculate that if VEGF and
its receptors play a role in recurrent
miscarriage, the disturbance may occur in
the maternal tissues rather than in the
placenta.
Interestingly, in the two trophoblast layers
lining the placental villi, VEGFR-2
immunoreactivity was consistently stronger
in the cytotrophoblasts underlying the
syncytiotrophoblasts. Clark et al. (1996)
have earlier shown such a staining pattern
for VEGF and VEGFR-1, whereas as
regards these two antigens we observed
equally strong staining in the cyto- and
syncytiotrophoblasts. These results may
imply a heterogeneous nature of trophoblast
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populations, cells characterized by a variety
of secretory action (Ross and Reith 1985,
Talamentes and Ogren 1988).
Our finding of expression of the receptor
for VEGF-C, VEGFR-3, in the vascular
endothelium of placental villi, but not of the
decidua, might indicate different expression
levels of VEGFR-3 in blood vascular
endothelia of different origins. It might also
indicate the overall heterogeneity of blood
vascular endothelium, an organ which
displays different characteristics at different
sites of the body (Fajardo 1989).
Tie-1 and Tie-2 may be associated with
recurrent miscarriage as, compared with
healthy controls, their expression was
diminished in the placental villous
trophoblasts and in the decidual vascular
endothelium of affected women.
Interestingly, Tie-1 and Tie-2 were also
expressed in a trophoblast population
invading the maternal decidua, whereas
VEGF, and VEGFR-1, -2 and -3 were not.
Tie-1 and Tie-2 might thus also play a role
in implantation, where trophoblast invasion
is a crucial event.
In the BO group, we observed intriguing
lumena resembling blood vessels, but
which were negative for von Willebrandt
factor. As the inner cell lining of these
luminal structures showed
immunoreactivity for all the antigens
studied, VEGF, VEGFR-1, -2, -3, Tie-1 and
-2, it might be that they represent blood
vessels that, for some reason, had not
matured enough to express vWF. It is
known that during embryogenesis the
expression of VEGF receptors, followed by
the expression of Tie receptors, both
precede that of von Willebrandt factor,
which is considered to be a marker of
mature endothelium (Partanen and Dumont
1999).
These results provide data indicating that
there might be different requirements as
regards receptor expression related to the
cell and tissue type, as well as to the nature
of miscarriage. By focusing research on
vascular growth and function, we might be
able to get closer to the mystery of
recurrent miscarriages, and perhaps even
develop a therapeutic tool.
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VEGF, PlGF and Tie-1 in healthy term placenta
We demonstrated strong expression of
VEGF-B and VEGF-C mRNAs in the
placenta by Northern blotting. However,
Clark et al. (1998b) did not observe any
VEGF-B or VEGF-C mRNA signals in
term placenta in in situ hybridization. Thus,
the cell types expressing VEGF-B and
VEGF-C in the placenta remain to be
identified.
The expression patterns of VEGF and PlGF
suggest a paracrine mode of action, as the
mRNA and protein were localized in
different cells. The results of this study are
not entirely consistent with data from
healthy term placentae from other groups
(see Figure 2). For example, VEGF mRNA
has also been demonstrated in extravillous
trophoblasts, maternal and fetal-derived
macrophages, and in the amnion (Sharkey
et al. 1993). Positive VEGF
immunoreactivity has been localized to
villous cytotrophoblasts (Ahmed et al.
1995) and syncytiotrophoblasts (Jackson et
al. 1994, Shiraishi et al. 1996), as well as
extravillous trophoblasts (Cooper et al.
1995, Shiraishi et al. 1996).
Our results on PlGF mRNA localization in
the placenta were only partly confirmed by
Khaliq et al., who demonstrated that PlGF
mRNA is present in the trophoblasts lining
the villi, and in addition in the villous
mesenchyme as well as in the amnion and
cells within the chorion. They also
described PlGF immunoreactivity in
placental villi as well as in the media of
blood vessels (Khaliq et al. 1999).
The reason for these differences in data
from various groups is not entirely clear.
Taken together, the data suggest that
VEGF, VEGF-B, VEGF-C and PlGF may
form a complex regulatory system
underlying placental vascular growth and
maintenance.
Comparison of early and term healthy placentae
In the present work VEGF and Tie-1
expression were analyzed in both early and
term healthy placentae. The latter were
analyzed by in situ hybridization and by
immunohistochemistry using monoclonal
antibodies, and early placentae by
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immunohistochemistry using polyclonal
antibodies. Despite these methodological
differences it appears that during both early
and term pregnancy, VEGF and Tie-1 are
localized to the vascular endothelium. In
addition, they are found in the trophoblasts.
It may be speculated that in addition to their
functions in the vascular endothelium, both
these factors might be involved in
trophoblastic function throughout
pregnancy.
Decreased serum Tie-1 in pre-eclampsia
The aetiology of pre-eclampsia still remains
an enigma. As vascular endothelial
dysfunction is typical of this condition
(Dekker and van Geijn 1996, Morris et al.
1996, Mushambi et al. 1996, Roberts et al.
1991, Roberts et al. 1989) we hypothesized
that Tie-1, expressed in endothelial cells,
might be associated with the condition. The
importance of Tie-1 in fetal and placental
vascular development is suggested by the
lethal phenotype of Tie-1 knock-out mice
(Sato et al. 1995), the prominent expression
of Tie-1 in umbilical veins of mouse
embryos (Korhonen et al. 1994), and the
data from Study I, i.e. the presence of Tie-1
in placental villous vascular endothelium
and trophoblasts.
In the non-pregnant women in our study,
circulating Tie-1 concentrations were
independent of oral contraceptive use.
During pregnancy, however, markedly
higher levels were found. The maternal
circulating extracellular domains of Tie-1
might be derived from the maternal
endothelium or placental trophoblasts
washed by maternal blood. They might also
originate from the fetus by diffusion across
the placenta, as Tie-1 levels in the umbilical
circulation were higher than those in the
maternal circulation.
The pre-eclamptic women in our study
showed lower serum Tie-1 concentrations
when compared with healthy women at the
same gestational ages. If this circulating
Tie-1 is derived from the placenta, the low
levels could be explained by the small
placental size seen in pre-eclampsia. If it is
derived from the maternal vascular
endothelium, one can speculate that the
vascular endothelial damage present in pre-
eclampsia (Roberts et al. 1989) would lead
to diminished release of circulating Tie-1.
Whether or not the circulating, though as
yet unidentified, Tie-1 ligand would then be
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more accessible to the endothelium-bound
receptors and perhaps further contribute to
the endothelial dysfunction, remains an
open question.
It is also tempting to speculate that the
observed low serum Tie-1 levels in pre-
eclampsia, which were even lower than in
non-pregnant subjects, are associated with
the shallow invasion of trophoblasts into
the endo- and myometrium in pre-
eclampsia (Brosens et al. 1972).
Pregnancy-associated binding of VEGF
Because VEGF, being such a strong
stimulator of vasculo- and angiogenesis, is
present in human reproductive tissues
(Charnock-Jones et al. 1993, Jackson et al.
1994, Sharkey et al. 1993), it is logical to
assume that its action there needs to be
tightly regulated. At the time of the present
study (IV), little was known about such
regulation.
As we noticed the absence of VEGF
immunoreactivity in maternal serum and
amniotic fluid, we speculated that either it
was not present in these body fluids, or that
it may be bound by some compound(s). We
then demonstrated the presence of a high
molecular weight compound binding VEGF
in maternal serum and in amniotic fluid.
This binding activity was pregnancy-
specific, as it disappeared from the
maternal circulation during the first few
days postpartum, and was not present in
sera from non-pregnant women or in sera
from men. Neither was it observed in the
umbilical circulation.
On the basis of our results it appears that
strong VEGF binding is required in the
maternal circulation and in tissues in
contact with amniotic fluid. In both fluids
this binding capacity also increases with
advancing gestational age. The placenta and
the fetal intestine appear to act as tight
barriers against possible diffusion of this
molecule to the fetal circulation, where it
was not observed.
Prior to our study Kendall and Thomas had
described the soluble form of VEGFR-1
(Kendall and Thomas 1993, Kendall et al.
1996). We were not sure, however, if
sVEGFR-1 was the high molecular
compound we observed in amniotic fluid,
as we noted full recovery of added PlGF,
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and VEGFR-1 is known to bind PlGF
(Sawano et al. 1996). Later, during
publication of our results, other studies on
pregnancy-associated binding of VEGF
were published (Anthony et al. 1997, Banks
et al. 1998, Clark et al. 1998a). It became
evident that the identity of the VEGF-
binding high molecular weight compound
in amniotic fluid was, after all, a
pregnancy-associated soluble form of
VEGFR-1 capable of forming multimeric
complexes (Banks et al. 1998).
Undoubtedly, identification of the
pregnancy-associated soluble form of
VEGFR-1 adds to our understanding of the
molecular control of vascular growth in
pregnancy. Future studies on the
interactions between this receptor and its
ligand VEGF should add to our
understanding of the control of vascular
growth during pregnancy.
Effects of diabetes and pre-eclampsia
on amniotic fluid soluble VEGF receptor-1
Understanding the interactions between
VEGF and its receptors during pregnancy
might help to elucidate the pathophysiology
of complicated pregnancies, but so far only
a little data is available on this subject. One
way to approach the issue was to measure
amniotic fluid sVEGFR-1 concentrations.
As amniotic fluid VEGF is readily bound
by sVEGFR-1 (IV, Banks et al. 1998, Clark
et al. 1998a), and as the commercially
available ELISA (Quantikine, R&D
Systems) only recognizes free VEGF, our
work was limited to studying amniotic fluid
sVEGFR-1 only.
Pre-eclampsia is clearly associated with
increased amniotic fluid sVEGFR-1 levels,
whether it occurs alone or is superimposed
on diabetes. The in-built weakness of
studies such as ours (V) is the difference in
gestational ages at delivery between
severely ill pre-eclamptic women and
healthy controls. However, our hypothesis
of an association between pre-eclampsia
and amniotic fluid sVEGFR-1 levels is
supported by the finding that these levels
were higher in diabetic patients with
superimposed pre-eclampsia than in those
without pre-eclampsia, and by the fact that
these subjects delivered at the same
gestational age.
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Whether the increased concentrations of
amniotic fluid sVEGFR-1 in pre-eclampsia
are derived from the placenta, which was
shown to secrete sVEGFR-1 (V), or some
other tissue such as the fetal membranes, or
perhaps fetal urine, is not known. Diffusion
across the placenta from the maternal
circulation is a possibility as well. This
appears to be unlikely, as the VEGF-
binding capacity in third trimester amniotic
fluid is some 100-times stronger than in
maternal serum. It has to be remembered,
however, that no data on the concentrations
of sVEGFR-1 in sera from pre-eclamptic
women are available.
There was a tendency towards lower
concentrations of amniotic fluid sVEGFR-1
in diabetic patients compared with healthy
controls, though this difference lacked
statistical significance. Those diabetic
women with superimposed pre-eclampsia,
however, tended to have higher levels than
those without pre-eclampsia. Whether
changes in amniotic fluid soluble VEGFR-1
levels precede the symptoms of pre-
eclampsia, and could perhaps be used for
evaluating the risk of developing this
condition, remains an open question.
As in pre-eclampsia, in pregnancies
complicated by fetal growth restriction,
inadequate physiological remodelling of
uterine blood vessels is observed (Brosens
et al. 1977). We therefore included women
whose fetuses suffered from growth
restriction (FGR) in our study. In contrast
to the pre-eclamptic subjects, we found no
difference in amniotic fluid sVEGFR-1
concentrations between the FGR group and
controls. This might, however, have been a
result of the small number of cases in the
FGR group, and I consider that the
hypothesis of altered amniotic fluid
sVEGFR-1 concentrations in association
with FGR has not yet been thoroughly
tested.
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SUMMARY AND CONCLUSIONS
During pregnancy, vascular growth is rapid,
and there has to be a well controlled
balance of promoting and hindering factors.
The VEGF family of growth factors, along
with their receptors, as well as the Tie
receptors, have proved to be potential
angiogenic agents essential for the
continuation of pregnancy in mice
(Claesson-Welsh 1999). They might also
play a role in the human placenta, where
they are expressed in both early and term
pregnancy. In particular, VEGF may play a
role in the well-being of the human fetus, as
free VEGF is abundant in umbilical cord
blood, yet in the maternal circulation and in
amniotic fluid it is tightly bound by the
soluble form of VEGFR-1.
In cases of recurrent miscarriage the
expression of these agents in the placenta
and decidua shows cell-type-specific
changes. An inspiring vision is that these
molecules could be used to protect such
women from further miscarriages.
During the third trimester of pregnancy,
pre-eclamptic women, when compared with
healthy pregnant women, have higher
amniotic fluid concentrations of soluble
VEGFR-1, and lower serum levels of Tie-1.
In contrast, women with insulin-dependent
diabetes mellitus have lower amniotic fluid
soluble VEGFR-1 levels than do healthy
women. However, if diabetic women have
superimposed pre-eclampsia, the amniotic
fluid soluble VEGFR-1 levels are higher
than in amniotic fluid from women with
diabetes alone. Based on these data it is
tempting to hypothesize that Tie-1, or
perhaps soluble VEGFR-1, could be
utilized as a marker to predict the risk of
pre-eclampsia. Such a marker would be
especially helpful for risk groups, such as
diabetic pregnant women.
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